DIPG-17. DYSREGULATED PURINE METABOLISM IN A LETHAL CHILDHOOD BRAINSTEM TUMOR REVEALS NEW TREATMENT STRATEGIES WITH OLD …
I Mersich, S Congrove, M Horchar, R Caceres… - Neuro …, 2024 - ncbi.nlm.nih.gov
The median survival of children with Diffuse Intrinsic Pontine Glioma (DIPG), an incurable
brainstem cancer is less than 1 year. Radiation therapy is the only treatment that offers a …
brainstem cancer is less than 1 year. Radiation therapy is the only treatment that offers a …
Therapeutically targeting dysregulated purine metabolism in DIPG
I Mersich - 2023 - rave.ohiolink.edu
Diffuse intrinsic pontine glioma (DIPG) is an incurable brainstem tumor, primarily diagnosed
in children. The median survival of DIPG is 8-11 months and 5-year overall survival is …
in children. The median survival of DIPG is 8-11 months and 5-year overall survival is …
DIPG-03. Therapeutic targeting of purine biosynthesis in DIPG
I Mersich, B Dasgupta - Neuro-Oncology, 2022 - ncbi.nlm.nih.gov
Diffuse intrinsic pontine glioma (DIPG) is an incurable brainstem malignancy in children.
Little progress has been made in treating this deadly disease due to its inoperable location …
Little progress has been made in treating this deadly disease due to its inoperable location …
TMET-35. ONE CARBON AND NUCLEOTIDE METABOLISM ARE NOVEL TARGETS IN PEDIATRIC BRAINSTEM TUMORS
I Mersich, A D'Alessandro, P Desai, L Sallans… - Neuro …, 2022 - ncbi.nlm.nih.gov
Diffuse intrinsic pontine glioma (DIPG) are inoperable tumors of the brainstem with no cure.
The median survival of children with DIPG is less than 2 years and 5-year overall survival is …
The median survival of children with DIPG is less than 2 years and 5-year overall survival is …
DIPG-14. PROTEOGENOMICS PROFILING REVEALS ENRICHED NON-HISTONE PROTEIN METHYLTRANSFERASES AS NEW THERAPEUTIC TARGETS IN DIPG
AK Anguraj Vadivel, S Pajovic, P Patel… - Neuro …, 2023 - academic.oup.com
Diffuse intrinsic pontine glioma (DIPG) is a devastating brain tumour arising in the
brainstems of children. Despite advances in genomics and treatments, the survival rate …
brainstems of children. Despite advances in genomics and treatments, the survival rate …
DIPG-69. CHARACTERISTICS OF PATIENTS≥ 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG …
Diffuse intrinsic pontine gliomas (DIPG) are deadly childhood brainstem tumors that
comprise approximately half of all pediatric high-grade gliomas (HGG). Recurrent, clonal …
comprise approximately half of all pediatric high-grade gliomas (HGG). Recurrent, clonal …
DIPG-42. MAPPING THE DNA METHYLATION LANDSCAPE OF DIPG REVEALS NOTABLE METHYLOME VARIABILITY RESPONSIVE TO PHARMACOLOGIC …
A Tetens, A Martin, A Arnold, O Novak, A Idrizi… - Neuro …, 2023 - ncbi.nlm.nih.gov
Diffuse intrinsic pontine glioma (DIPG) is an incurable pediatric brainstem tumor, driven by
the H3K27M mutation leading to epigenetic dysregulation. Epigenomic analyses of DIPG …
the H3K27M mutation leading to epigenetic dysregulation. Epigenomic analyses of DIPG …
DIPG-43. CLINICAL AND MOLECULAR CHARACTERISTIC OF A NEW SUBTYPE OF DMG, H3K27-ALTERED WITH MAPK-ACTIVATING CO-DRIVER MUTATIONS
L Auffret, Y Ajlil, T Kergrohen… - Neuro …, 2023 - academic.oup.com
Pediatric-type diffuse high grade gliomas are aggressive brain cancers in children which to
date lack effective treatment options and remain largely understudied. Even though genomic …
date lack effective treatment options and remain largely understudied. Even though genomic …
DIPG-58. TARGETING DISORDERED DNA METHYLATION IN DIPG TO CONSTRAIN VARIABILITY AND INDUCE IMMUNE SIGNALING
AR Tetens, AM Martin, A Arnold, OV Novak… - Neuro …, 2024 - ncbi.nlm.nih.gov
BACKGROUND Diffuse Intrinsic Pontine Glioma (DIPG) is a universally fatal pediatric brain
cancer characterized by the histone H3 K27M mutation. The known downstream …
cancer characterized by the histone H3 K27M mutation. The known downstream …
DIPG-39. NOVEL PROTEOMIC ANALYSIS REVEALS EPIGENETIC THERAPEUTIC TARGETS IN PEDIATRIC GLIOMA
INTRODUCTION Diffuse midline glioma is a highly morbid pediatric cancer. Up to 80%
harbor Histone H3K27M mutation, which alters Histone H3 post-translational modifications …
harbor Histone H3K27M mutation, which alters Histone H3 post-translational modifications …